Offer for Cambridge Antibody

AstraZeneca PLC
07 July 2006

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, IN, INTO OR
FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE
RELEVANT LAWS OF SUCH JURISDICTION



                   Posting of Compulsory Acquisition Notices

Further to AstraZeneca's announcement on 30 June 2006 regarding its intention to
exercise its rights pursuant to the provisions of Schedule 2 of the Interim
Regulations to acquire compulsorily, on the same terms as the Offer, the
remaining CAT Shares (including shares underlying CAT ADSs) in respect of which
the Offer has not been accepted, AstraZeneca announces the despatch today of
compulsory acquisition notices to CAT Shareholders who have not accepted the
Offer.

CAT Shareholders who wish to accept the Offer and who have not already done so
should, if their CAT Shares are held in certificated form, complete and return
their Form of Acceptance as soon as possible in accordance with the instructions
printed on it. CAT Shareholders who hold CAT Shares in uncertificated form and
who have not yet accepted the Offer are reminded to follow the CREST procedure
set out in the Offer Document.

Defined terms used in this announcement have the same meanings as in the Offer
Document dated 23 May 2006.



Enquiries:

AstraZeneca

Media Enquiries:

Steve Brown (London)                          [phone]

Edel McCaffrey (London)                       [phone]

Staffan Ternby (Sweden)                       [phone]

Analyst/Investor Enquiries:

Jonathan Hunt (London)                        [phone]

Mina Blair (London)                           [phone]

Ed Seage (US)                                 [phone]

Jorgen Winroth (US)                           [phone]

Goldman Sachs International                   [phone]

Guy Slimmon

Mark Sorrell



This announcement is for informational purposes only and does not constitute an
offer to sell or an invitation to purchase any securities or the solicitation of
an offer to buy any securities, pursuant to the Offer or otherwise. This
announcement also does not constitute a Solicitation / Recommendation Statement
under the rules and regulations of the US Securities and Exchange Commission
(the 'SEC'). The Offer is being made solely by means of the Offer Document and
the Form of Acceptance accompanying the Offer Document, which contain the full
terms and conditions of the Offer, including details of how the Offer may be
accepted. In the United States, AstraZeneca has filed a Tender Offer Statement
containing the Offer Document and other related documentation with the SEC on
Schedule TO and CAT has filed a Solicitation/Recommendation Statement with the
SEC on Schedule 14D-9. Free copies of the Schedule TO, the Schedule 14D-9 and
the other related documents filed by AstraZeneca or CAT in connection with this
Offer are available on the SEC's website at www.sec.gov. The Offer Document and
Acceptance Forms accompanying the Offer Document have been made available to all
CAT Shareholders at no charge to them. CAT Shareholders are advised to read the
Offer Document and the accompanying Acceptance Forms as they contain important
information. CAT Shareholders in the United States are also advised to read the
Tender Offer Statement and the Solicitation/Recommendation Statement as they
contain important information.

Goldman Sachs International, which is authorised and regulated by the Financial
Services Authority, is acting exclusively for AstraZeneca and no one else in
connection with the Offer and will not be responsible to anyone other than
AstraZeneca for providing the protections afforded to clients of Goldman Sachs
International or for providing advice in relation to the Offer or any other
matters referred to in this announcement.

The availability of the Offer to CAT Shareholders who are not resident in and
citizens of the United Kingdom or the United States may be affected by the laws
of the relevant jurisdictions in which they are located or of which they are
citizens. Such persons should inform themselves of, and observe, any applicable
legal or regulatory requirements of their jurisdictions. Further details in
relation to overseas shareholders are contained in the Offer Document.

The Loan Notes which will be issued pursuant to the Loan Note Alternative have
not been, and will not be, listed on any stock exchange and have not been, and
will not be, registered under the Securities Act or under any relevant laws of
any state or other jurisdiction of the United States, nor have clearances been,
nor will they be, obtained from the securities commission or similar authority
of any province or territory of Canada and no prospectus has been, or will be,
filed, or registration made, under any securities law of any province or
territory of Canada, nor has a prospectus in relation to the Loan Notes been,
nor will one be, lodged with, or registered by, the Australian Securities and
Investments Commission, nor have any steps been taken, nor will any steps be
taken, to enable the Loan Notes to be offered in compliance with applicable
securities laws of Japan. Accordingly, unless an exemption under relevant
securities laws is available, the Loan Notes may not be offered, sold, re-sold
or delivered, directly or indirectly, in, into or from the United States or any
other Loan Note Restricted Jurisdiction in which an offer of Loan Notes would
constitute a violation of relevant laws or require registration of the Loan
Notes, or to or for the account or benefit of any US person or resident of any
other Loan Note Restricted Jurisdiction.

Unless otherwise determined by AstraZeneca and permitted by applicable law and
regulation, subject to certain exemptions, the Offer will not be capable of
acceptance from or within a Restricted Jurisdiction. Accordingly, copies of this
announcement must not be, directly or indirectly, mailed or otherwise forwarded,
distributed or sent in, into or from a Restricted Jurisdiction and persons
receiving this announcement (including custodians, nominees and trustees) should
observe these restrictions and must not mail or otherwise distribute this
announcement in, into or from any such jurisdictions.


                      This information is provided by RNS
            The company news service from the London Stock Exchange